Clinical Trials
GI Carcinoma
Phase 2 Open-label Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects with Advanced or Inoperable Hepatocellular Carcinoma.
- Principal Investigator: Thomas Cosgriff, M.D.

